Scarica l'app Stockscreener
0.4371
4.98%
-0.0229
Precedente Chiudi:
$0.46
Aprire:
$0.4662
Volume 24 ore:
5.87M
Relative Volume:
0.44
Capitalizzazione di mercato:
$101.17M
Reddito:
$44.05M
Utile/perdita netta:
$-156.16M
Rapporto P/E:
-0.6361
EPS:
-0.6872
Flusso di cassa netto:
$-158.51M
1 W Prestazione:
-12.70%
1M Prestazione:
-80.91%
6M Prestazione:
-87.37%
1 anno Prestazione:
-66.38%
Intervallo 1D:
$0.4359
$0.4815
Intervallo di 1 settimana:
$0.4359
$0.5686
Portata 52W:
$0.3312
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.4371 | 101.17M | 44.05M | -156.16M | -158.51M | -0.6872 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Scrutiny After Sharp February Plunge - AD HOC NEWS
Gossamer Bio options imply 46.1% move in share price post-earnings - Yahoo Finance
Gossamer Bio Inc Stock (ISIN: US38198T1034) Surges on Clinical Momentum and Analyst Optimism - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
GOSS Stock Quote Price and Forecast - CNN
GOSS Stock Price, Quote & Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GOSS Gossamer Bio NASDAQ $0.56 10 Mar 2026: Pre-market ahead of Mar 12 earnings - Meyka
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Can Gossamer Bio Inc withstand a market correction2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Gossamer Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts remain bullish on Gossamer Bio (GOSS) citing undervaluation - MSN
683 Capital Management, LLC Increases Stake in Gossamer Bio Inc - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HC Wainwright Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00 - MarketBeat
GOSS: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Oppenheimer Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $3.00 - MarketBeat
Oppenheimer Maintains Outperform Rating, Lowers PT on Gossamer B - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - sharewise.com
GOSS: Announces Topline Results for Phase 3 PROSERA Trial — LEVI & KORSINSKY, LLP - The Malaysian Reserve
Gossamer Bio to Report Q4 2025 Earnings on Thursday - National Today
Gossamer Bio (GOSS) to Release Earnings on Thursday - MarketBeat
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of "Hold" by Brokerages - MarketBeat
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Stockholders to Connect - ACCESS Newswire
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - MEXC
2026-03-01 | Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Should You Buy Gossamer Bio Inc (GOSS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-02-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring the 1,395.85% Potential Upside for Investors - DirectorsTalk Interviews
Gossamer Bio (NASDAQ:GOSS) Downgraded to Hold Rating by The Goldman Sachs Group - MarketBeat
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS) - The Globe and Mail
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Gossamer, Grail down by more than half after late-stage misses - biocentury.com
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):